Literature DB >> 25564572

Activation of IL6/IGFIR confers poor prognosis of HBV-related hepatocellular carcinoma through induction of OCT4/NANOG expression.

Te-Sheng Chang1, Yu-Chih Wu2, Ching-Chi Chi3, Wei-Chi Su4, Pey-Jium Chang5, Kam-Fai Lee6, Tao-Hsin Tung7, Jui Wang8, Jun-Jen Liu9, Shui-Yi Tung10, Liang-Mou Kuo11, Hong-Nerng Ho12, Thai-Yen Ling13, Yen-Hua Huang14.   

Abstract

PURPOSE: To unravel the role of interleukin (IL)-6 and insulin-like growth factor (IGF)-I receptor (IGFIR) in expressing stemness-related properties and to evaluate the prognostic values of pluripotent transcription factor OCT4/NANOG, and IGFIR in hepatocellular carcinoma (HCC). EXPERIMENTAL
DESIGN: Serum levels of IL6 were detected using ELISA assays (n = 120). The effects of IL6/IGFI on stemness expression in HCC were examined using OCT4/NANOG promoter luciferase reporter, RNA interference, secondary sphere formation, side population, and xenograft animal models. The OCT4/NANOG protein and phospho-IGFI receptor (p-IGFIR) in tissues were detected by Western blotting (n = 8) and immunohistochemical staining (n = 85). OCT4, NANOG, and IGFIR expression levels in tissues (n = 191) were analyzed by real-time qRT-PCR and was correlated with early tumor recurrence using the Kaplan-Meier survival analysis.
RESULTS: A high positive correlation between the expression levels of OCT4/NANOG and IGFIR/p-IGFIR in human HCC tissues was observed. The concurrent expression of OCT4/NANOG/IGFIR was mostly confined to hepatitis B virus (HBV)-related HCC (HBV-HCC) and was significantly correlated with early tumor recurrence. High serum levels of IL6 were significantly correlated with high OCT4/NANOG expression. IL6 stimulated an autocrine IGFI/IGFIR expression STAT3 dependently, which stimulated stemness-related properties in both the cell lines and the xenografted mouse tumors. The inhibition of IGFIR activation by either RNA interference or by treatment with the inhibitor picropodophyllin (PPP) significantly suppressed the IL6-induced stemness-related properties both in vitro and in vivo.
CONCLUSIONS: The expression of pluripotency-related genes is associated with early tumor recurrence and is regulated by IL6-induced IGF/IGFIR activation, particularly in HBV-HCC. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25564572     DOI: 10.1158/1078-0432.CCR-13-3274

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  54 in total

1.  Multiple novel hepatocellular carcinoma signature genes are commonly controlled by the master pluripotency factor OCT4.

Authors:  Chao Ye; Xiaoqian Zhang; Xinyu Chen; Qingyi Cao; Xiaobing Zhang; Yanwen Zhou; Wenxin Li; Liangjie Hong; Haiyang Xie; Xiaoli Liu; Hongcui Cao; Ying-Jie Wang; Bo Kang
Journal:  Cell Oncol (Dordr)       Date:  2019-12-17       Impact factor: 6.730

Review 2.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

3.  IL6-mediated inflammatory loop reprograms normal to epithelial-mesenchymal transition+ metastatic cancer stem cells in preneoplastic liver of transforming growth factor beta-deficient β2-spectrin+/- mice.

Authors:  Abhisek Mitra; Jun Yan; Xueqing Xia; Shouhao Zhou; Jian Chen; Lopa Mishra; Shulin Li
Journal:  Hepatology       Date:  2017-01-20       Impact factor: 17.425

4.  Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347.

Authors:  Hongwu Fan; Guangyao Liu; Changfu Zhao; Xuefeng Li; Xiaoyu Yang
Journal:  Oncol Lett       Date:  2016-11-21       Impact factor: 2.967

5.  Interleukin-6 enhances cancer stemness and promotes metastasis of hepatocellular carcinoma via up-regulating osteopontin expression.

Authors:  Chao-Qun Wang; Hao-Ting Sun; Xiao-Mei Gao; Ning Ren; Yuan-Yuan Sheng; Zheng Wang; Yan Zheng; Jin-Wang Wei; Kai-Li Zhang; Xin-Xin Yu; Yin Zhu; Qin Luo; Lu-Yu Yang; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

6.  Hepatitis B and Hepatitis C Virus Infection Promote Liver Fibrogenesis through a TGF-β1-Induced OCT4/Nanog Pathway.

Authors:  Wenting Li; Xiaoqiong Duan; Chuanlong Zhu; Xiao Liu; Andre J Jeyarajan; Min Xu; Zeng Tu; Qiuju Sheng; Dong Chen; Chuanwu Zhu; Tuo Shao; Zhimeng Cheng; Shadi Salloum; Esperance A Schaefer; Annie J Kruger; Jacinta A Holmes; Raymond T Chung; Wenyu Lin
Journal:  J Immunol       Date:  2022-01-12       Impact factor: 5.422

7.  High expression of OCT4 is frequent and may cause undesirable treatment outcomes in patients with acute myeloid leukemia.

Authors:  Jia-Yu Yin; Qin Tang; Ling-Ling Zhai; Ling-Yu Zhou; Jun Qian; Jiang Lin; Xiang-Mei Wen; Jing-Dong Zhou; Ying-Ying Zhang; Xiao-Wen Zhu; Zhao-Qun Deng
Journal:  Tumour Biol       Date:  2015-07-09

8.  Oct3/4 is potentially useful for the suppression of the proliferation and motility of hepatocellular carcinoma cells.

Authors:  Minoru Tomizawa; Fuminobu Shinozaki; Yasufumi Motoyoshi; Takao Sugiyama; Shigenori Yamamoto; Naoki Ishige
Journal:  Oncol Lett       Date:  2018-08-10       Impact factor: 2.967

Review 9.  Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.

Authors:  Mitsuro Kanda; Hiroyuki Sugimoto; Yasuhiro Kodera
Journal:  World J Gastroenterol       Date:  2015-10-07       Impact factor: 5.742

10.  Long noncoding RNA lncTCF7, induced by IL-6/STAT3 transactivation, promotes hepatocellular carcinoma aggressiveness through epithelial-mesenchymal transition.

Authors:  Jun Wu; Jun Zhang; Bin Shen; Kai Yin; Jianwei Xu; Wencan Gao; Lihong Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.